Antihypertensive drug use and the risk of prostate cancer (Canada) - Wikidata - awgldk - TriplyDB

Antihypertensive drug use and the risk of prostate cancer (Canada)

Antihypertensive drug use and the risk of prostate cancer (Canada)

http://www.wikidata.org/entity/Q28209807

about

sameAs

Renin-angiotensin system blockade: Its contribution and controversy Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression Expression of Cathepsins B, D, and G in Isocitrate Dehydrogenase-Wildtype Glioblastoma.Sympathetic Neurotransmitters and Tumor Angiogenesis-Link between Stress and Cancer Progression.Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies.The sympathetic nervous system induces a metastatic switch in primary breast cancer.Tumor interactions with soluble factors and the nervous system.Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer.Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened.Biobehavioral influences on cancer progression.Impact of stress on cancer metastasis Stress influences on anoikis Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.The influence of bio-behavioural factors on tumour biology: pathways and mechanisms.A pharmacological primer of biased agonism Neural regulation of hematopoiesis, inflammation, and cancer.Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention.Propranolol Reduces Cancer Risk: A Population-Based Cohort Study.Acute activation of β2-adrenergic receptor regulates focal adhesions through βArrestin2- and p115RhoGEF protein-mediated activation of RhoA.Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint Neuroendocrine influences on cancer progression.β-blockers: a novel class of antitumor agents.Statins and prostate cancer diagnosis and grade in a veterans population.Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD).Src activation by β-adrenoreceptors is a key switch for tumour metastasis.Behavioral stress accelerates prostate cancer development in mice.Pharmacological blockade of a β(2)AR-β-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model Neuroendocrine influences on cancer biology.β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study Neuroendocrine modulation of cancer progression.Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines.A pilot study of blood epinephrine levels and CREB phosphorylation in men undergoing prostate biopsies.Obstructive sleep apnea and cancer: Epidemiologic links and theoretical biological constructs.β-adrenergic-blocking drugs and melanoma: current state of the art.Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system.Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis.

P2860

Q26827221-97B5DA7E-2CC7-461B-84C8-4C0729143CF0 Q27027373-B5F98779-9F91-4240-82FE-17D091FC5B44 Q33734645-889AEAB6-1E54-412D-A8C9-2763274B5431 Q33870774-3A14C03A-951D-4173-AA70-9F0D6369BC08 Q34005101-4957FB45-A8EE-4B98-8551-A397557D492B Q34134468-F775E43C-BA0A-40B7-A5B0-65A4559FFC9F Q34142510-346EDDD6-F5FF-413B-AF49-6F73792D242D Q34144147-3FFAD106-7374-4C2B-AB5A-376AF265A4A8 Q34441859-55B213C9-C1EF-4A87-86D4-4BA9FCCD7466 Q34447713-31237B37-D790-4E90-BA25-D1B4AF335AA0 Q34569251-E6AA7884-C226-442B-9574-C09A97FBB860 Q34779850-924C088E-83EE-4DDB-8D00-34AE04945460 Q34837191-405832A2-96F3-4F06-8DDC-22784F28AD16 Q35135129-6939FF9B-E799-468F-8690-945742A9B139 Q35238406-6930FFE9-2CE7-49DB-999B-E85063AEDB79 Q35560457-A9FF87FD-915B-490B-BC6E-E6223EADCCB2 Q35586501-7A265967-9D52-44EC-9CF5-A0C05119C959 Q35681985-6FD484AE-4612-45C2-B785-21C4A1B28ECD Q35747302-2C566FA3-1166-4DD1-8BA5-C21E3E638AE1 Q35858235-0AF34236-2BCF-4655-9142-5DC4EB64AEE3 Q36003618-FD108251-F6B7-4E25-8406-E0B5C34C66D2 Q36088013-5DE2ED1F-3818-478B-BAAB-E7AD553F17C9 Q36092918-E16C3ED3-EED4-4D42-989C-7B88D9B4FC5F Q36306358-73C3F5E1-8ED1-4EA4-9DE3-8CEE0C07FBC2 Q36443830-3DC81A9F-9693-45FC-8B4E-EC3937427522 Q36449867-D198D524-CCBF-4194-A9C7-774864E3834F Q36472011-B303E593-5533-40C0-B9FA-2043122C80A8 Q36579843-5F5335AE-DDF2-4A6B-A443-9FF7E04333DB Q36580367-2B383234-D515-4CE6-B4C3-81B3E8FA7B3E Q36618617-35391FC0-9F66-4940-B204-317F157DF848 Q36713229-C3732A11-0E11-4173-85A0-86ECE5BB803B Q36838466-A58AE9F0-EC69-43D6-BA88-8E8B3363F872 Q37071784-AB154459-F643-4031-AD50-3435E37A6EC7 Q37404693-3E35C722-305D-439C-9F31-5B46A2F8FC2D Q37406486-59FBB39B-AE5F-44F3-B2E5-3E54225CF47B Q37646929-D3B42D73-4078-467C-A188-717AF0A510AD Q37731479-5DEA365C-AD8C-479E-ACCD-D3732E1F9190 Q38068208-F33FE684-01EC-433E-BA5A-64984D79439C Q38293740-AD2763BB-D3DA-4EBB-98A5-37085258AF74 Q38501336-AB534932-F0C1-43EE-9CCF-44E16092F033

P2860

Antihypertensive drug use and the risk of prostate cancer (Canada)

http://www.wikidata.org/entity/Q28209807

description

2004 nî lūn-bûn

@nan

2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Antihypertensive drug use and the risk of prostate cancer (Canada)

@ast

Antihypertensive drug use and the risk of prostate cancer (Canada)

@en

Antihypertensive drug use and the risk of prostate cancer (Canada)

@nl

type

label

Antihypertensive drug use and the risk of prostate cancer (Canada)

@ast

Antihypertensive drug use and the risk of prostate cancer (Canada)

@en

Antihypertensive drug use and the risk of prostate cancer (Canada)

@nl

prefLabel

Antihypertensive drug use and the risk of prostate cancer (Canada)

@ast

Antihypertensive drug use and the risk of prostate cancer (Canada)

@en

Antihypertensive drug use and the risk of prostate cancer (Canada)

@nl

P1433

Q28209807-D8A91216-D8B0-4ED1-B6BB-1203F4558F7C

P1476

Q28209807-88E62729-C9A5-4B2E-8C54-735E40345A14

P2093

Q28209807-59085706-47DA-43CB-9499-C2265762B786

Q28209807-6EC02CB0-C934-48BB-B89C-CFA46F4943E6

Q28209807-937AC38E-180C-474F-80E7-E405A172C337

Q28209807-A1C91BEF-717D-4778-A8E5-3F87A5270426

P2888

Q28209807-A02C6400-6C3C-4671-9D7A-8BEA7192226D

P304

Q28209807-DF11BD25-1BA3-4BBC-AB2F-65443B14B72F

P31

Q28209807-69193E7E-20E6-40A6-9223-C11656FB8E43

P3181

Q28209807-70E5602D-69D8-4759-A320-9D63F1732F33

P356

Q28209807-0273E89F-12D6-4E5B-9F47-F3B4638B4E5B

P407

Q28209807-E6F2368B-7D90-4AFE-8796-EA4309E73463

P433

Q28209807-4A212F08-5213-45A2-8D1A-6E9354A5BB3B

P478

Q28209807-390C072A-B670-42A7-BA3D-2D68B2555047

P577

Q28209807-5C61F1D5-4408-4BB2-8F00-F815AE0332F8

P6179

Q28209807-D4787B9E-0A50-4463-9098-247A47F6F997

P698

Q28209807-5263A475-A519-41EE-BF06-D4AB858C9F6D

P921

Q28209807-1C045FEF-90B4-462A-9BA6-A682F838FADF

P3181

P356

B:CACO.0000036152.58271.5E

P1433

Cancer Causes & Control

P1476

Antihypertensive drug use and the risk of prostate cancer (Canada)

@en

P2093

François Harel

http://www.w3.org/2001/XMLSchema#string

François Meyer

http://www.w3.org/2001/XMLSchema#string

Isabelle Bairati

http://www.w3.org/2001/XMLSchema#string

Linda Perron

http://www.w3.org/2001/XMLSchema#string

P2888

b:caco.0000036152.58271.5e

P304

535-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3011411

http://www.w3.org/2001/XMLSchema#string

P356

10.1023/B:CACO.0000036152.58271.5E

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1037336722

http://www.w3.org/2001/XMLSchema#string

P698

15280632

http://www.w3.org/2001/XMLSchema#string

P921